Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...

Two years after first sharing her story, young cancer survivor Ellie Mai Murphy from Glasson says she is now focusing on ...

Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia. ・Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the ...

In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...

For adults with acute myeloid leukemia (AML), pretransplant NPM1 measurable residual disease (MRD) is prognostic for relapse, ...

Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...

A Winston-Salem father and daughter share their story of hope after a rare, perfect stem cell match helps him treat acute myeloid leukemia.

The life perspectives of two B.C. parents have shifted dramatically after their daughter got a life-changing diagnosis. In 2024, Lilah, who was only 16 months at the time, was diagnosed with acute ...

Limited "Joel's Wildfire" Series Expected to Raise Over $40,000 RICE LAKE, Wis., March 17, 2026 /PRNewswire/ -- Henry Repeating Arms, one of the country's leading firearms manufacturers, is donating a ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...